Johnson & Johnson (JNJ)
Johnson & Johnson - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Johnson & Johnson - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Piedmont Realty Trust Announces Pricing of $200,000,000 Exchangeable Senior Notes Offering
Warrants - Listing Confirmation: Product Listings
VPG Foil Resistors Partners with Source Technologi to Expand Footprint in India’s Aerospace & Defense, Telecom, and Semiconductor Sectors
Ouster Raises the Bar on High-Altitude Drone Mapping with The World’s First Native Color Lidar and 2x Accuracy & Precision Breakthrough on REV8 OS1 Max
IHT RECEIVES NYSE-AMERICAN APPROVAL FOR COMPLIANCE PLAN; REVERSE MERGER DISCUSSIONS CONTINUE
INVESTOR DEADLINE: AEVEX Corp. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit Before October 20, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - AVEX
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)